简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

哈罗公学重申2025年收入前景为2.7亿至2.8亿美元,得益于扩大商业足迹和投资组合绩效

2026-02-02 20:15

  • Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding
  • OneHarrow Initiative is Launched to Unify Branding under Harrow
  • Patrick W. Sullivan Promoted to Serve as Harrow's Chief Commercial Officer
  • MELT-300 and MELT-210 Programs on Track for New Drug Application Filings
  • Harrow's ImprimisRx Settles Pending Regulatory Matters with the California Board of Pharmacy

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。